Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

J. Horti, E. Juhasz, Z. Monostori, K. Maeda, S. Eckhardt, I. Bodrogi

Research output: Contribution to journalArticle

26 Citations (Scopus)


Purpose: The purpose of this phase I study was to evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), the recommended dose for phase II study, pharmacokinetics, and antitumor activity of TZT-1027 (soblidotin) in patients with non-small cell lung cancer (NSCLC) when administered every 3-4 weeks. Methods: Eligible patients had the following characteristics: stage III/b or IV NSCLC that was refractory to conventional therapy or for which no standard therapy was available; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2; adequate organ function; and age ≥20 and <75 years. The patients were administered TZT-1027 in escalating doses from 0.5 to 5.6 mg/m2. Pharmacokinetic samples were collected during each treatment course. Results: Forty-nine patients were enrolled. Three patients had DLTs, including neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The common toxicities included constipation, anorexia, alopecia, nausea, leukopenia, and neutropenia. One complete response and three partial responses were observed. The pharmacokinetic parameters (AUC and Cmax) of TZT-1027 tended to increase linearly with dose. Conclusions: DLTs included neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The MTD was 4.8 mg/m 2. The recommended phase II study dose of TZT-1027 is 4.8 mg/m 2 administered every 3-4 weeks.

Original languageEnglish
Pages (from-to)173-180
Number of pages8
JournalCancer Chemotherapy And Pharmacology
Issue number1
Publication statusPublished - Jun 1 2008



  • Dolastatin
  • Non-small cell lung cancer
  • Phase I study
  • TZT-1027

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this